Literature DB >> 25445561

Interventional oncology in multidisciplinary cancer treatment in the 21(st) century.

Andreas Adam1, Lizbeth M Kenny2.   

Abstract

Interventional oncology is an evolving branch of interventional radiology, which relies on rapidly evolving, highly sophisticated treatment tools and precise imaging guidance to target and destroy malignant tumours. The development of this field has important potential benefits for patients and the health-care system, but as a new discipline, interventional oncology has not yet fully established its place in the wider field of oncology; its application does not have a comprehensive evidence base, or a clinical or quality-assurance framework within which to operate. In this regard, radiation oncology, a cornerstone of modern cancer care, has a lot of important information to offer to interventional oncologists. A strong collaboration between radiation oncology and interventional oncology, both of which aim to cure or control tumours or to relieve symptoms with as little collateral damage to normal tissue as possible, will have substantial advantages for both disciplines. A close relationship with radiation oncology will help facilitate the development of a robust quality-assurance framework and accumulation of evidence to support the integration of interventional oncology into multidisciplinary care. Furthermore, collaboration between interventional oncology and radiation oncology fields will have great benefits to practitioners, people affected by cancer, and to the wider field of oncology.

Entities:  

Mesh:

Year:  2014        PMID: 25445561     DOI: 10.1038/nrclinonc.2014.211

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


  90 in total

Review 1.  Randomised trials in surgery: the burden of evidence.

Authors:  Kristoffer Lassen; Anne Hϕye; Truls Myrmel
Journal:  Rev Recent Clin Trials       Date:  2012-08

Review 2.  Advances in image-guided radiation therapy.

Authors:  Laura A Dawson; David A Jaffray
Journal:  J Clin Oncol       Date:  2007-03-10       Impact factor: 44.544

3.  Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy.

Authors:  A A Nicholson; D F Ettles; A Arnold; M Greenstone; J F Dyet
Journal:  J Vasc Interv Radiol       Date:  1997 Sep-Oct       Impact factor: 3.464

4.  Irreversible electroporation for treatment of liver cancer.

Authors:  Govindarajan Narayanan
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-05

5.  New intraluminal bypass tube for management of acutely obstructed left colon.

Authors:  P L Ruiz; E M Facciuto; M E Facciuto; J C Rodriguez Otero; J Pigatto; H Cominelli
Journal:  Dis Colon Rectum       Date:  1995-10       Impact factor: 4.585

6.  Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases.

Authors:  R S Stubbs; R J Cannan; A W Mitchell
Journal:  Hepatogastroenterology       Date:  2001 Mar-Apr

7.  Malignant gastric and duodenal stenosis: palliation by peroral implantation of a self-expanding metallic stent.

Authors:  I T Pinto
Journal:  Cardiovasc Intervent Radiol       Date:  1997 Nov-Dec       Impact factor: 2.740

8.  Prospective evaluation of a new self-expanding plastic stent for inoperable esophageal strictures.

Authors:  G Costamagna; S K Shah; A Tringali; M Mutignani; V Perri; M E Riccioni
Journal:  Surg Endosc       Date:  2003-03-07       Impact factor: 4.584

9.  Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases.

Authors:  Hyuk Hur; Yong Taek Ko; Byung Soh Min; Kyung Sik Kim; Jin Sub Choi; Seung Kook Sohn; Chang Hwan Cho; Heung Kyu Ko; Jong Tai Lee; Nam Kyu Kim
Journal:  Am J Surg       Date:  2008-09-11       Impact factor: 2.565

10.  Microwave ablation of lung malignancies: effectiveness, CT findings, and safety in 50 patients.

Authors:  Farrah J Wolf; David J Grand; Jason T Machan; Thomas A Dipetrillo; William W Mayo-Smith; Damian E Dupuy
Journal:  Radiology       Date:  2008-03-27       Impact factor: 11.105

View more
  10 in total

1.  Combined treatment of cholangiocarcinoma with interventional radiofrequency hyperthermia and heat shock protein promoter-mediated HSV-TK gene therapy.

Authors:  Jingfeng Luo; Jiali Zhou; Fengnan Xie; Yali Zhu; Fei Zhou; Shuanglin Zhang; Shaojie Jiang; Jie He; Jiaxin Liu; Xia Wu; Yanhua Zhang; Jihong Sun; Xiaoming Yang
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

Review 2.  The Role of Palliative Care in Oncology.

Authors:  Rajiv Agarwal; Andrew S Epstein
Journal:  Semin Intervent Radiol       Date:  2017-12-14       Impact factor: 1.513

Review 3.  Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper.

Authors:  Joseph P Erinjeri; Gabriel C Fine; Gosse J Adema; Muneeb Ahmed; Julius Chapiro; Martijn den Brok; Rafael Duran; Stephen J Hunt; D Thor Johnson; Jens Ricke; Daniel Y Sze; Beau Bosko Toskich; Bradford J Wood; David Woodrum; S Nahum Goldberg
Journal:  Radiology       Date:  2019-04-23       Impact factor: 11.105

4.  Multifunctional Nanocarriers-Mediated Synergistic Combination of Immune Checkpoint Inhibitor Cancer Immunotherapy and Interventional Oncology Therapy.

Authors:  Bongseo Choi; Dong-Hyun Kim
Journal:  Adv Nanobiomed Res       Date:  2021-08-02

Review 5.  The need for multidisciplinarity in specialist training to optimize future patient care.

Authors:  Alison C Tree; Victoria Harding; Aneel Bhangu; Venkatesh Krishnasamy; Dion Morton; Justin Stebbing; Bradford J Wood; Ricky A Sharma
Journal:  Nat Rev Clin Oncol       Date:  2016-11-29       Impact factor: 66.675

Review 6.  Development of Antioxidant COX-2 Inhibitors as Radioprotective Agents for Radiation Therapy-A Hypothesis-Driven Review.

Authors:  Markus Laube; Torsten Kniess; Jens Pietzsch
Journal:  Antioxidants (Basel)       Date:  2016-04-19

7.  Umbelliprenin is Potentially Toxic Against the HT29, CT26, MCF-7, 4T1, A172, and GL26 Cell Lines, Potentially Harmful Against Bone Marrow-Derived Stem Cells, and Non-Toxic Against Peripheral Blood Mononuclear Cells.

Authors:  Mohsen Rashidi; Seyed Ali Ziai; Taraneh Moini Zanjani; Ahad Khalilnezhad; Hamidreza Jamshidi; Davar Amani
Journal:  Iran Red Crescent Med J       Date:  2016-05-14       Impact factor: 0.611

8.  Structural Challenges of Providing Palliative Care for Patients with Breast Cancer.

Authors:  Tahereh Alsadat Khoubbin Khoshnazar; Maryam Rassouli; Mohammad Esmaeil Akbari; Farah Lotfi-Kashani; Syrus Momenzadeh; Shahpar Haghighat; Moosa Sajjadi
Journal:  Indian J Palliat Care       Date:  2016 Oct-Dec

9.  Salivary miRNA panel to detect HPV-positive and HPV-negative head and neck cancer patients.

Authors:  Yunxia Wan; Dimitrios Vagenas; Carolina Salazar; Liz Kenny; Chris Perry; Diego Calvopiña; Chamindie Punyadeera
Journal:  Oncotarget       Date:  2017-10-10

10.  CIRSE Clinical Practice Manual.

Authors:  Andreas H Mahnken; Esther Boullosa Seoane; Allesandro Cannavale; Michiel W de Haan; Rok Dezman; Roman Kloeckner; Gerard O'Sullivan; Anthony Ryan; Georgia Tsoumakidou
Journal:  Cardiovasc Intervent Radiol       Date:  2021-07-06       Impact factor: 2.740

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.